Clinical trial
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
NCT03418532
Study timeline
Study start (actual)2018-03-22Date precision: day
Registry last updated2023-03-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
EGFR-mutated NSCLC (Disorder)unresolved
Interventions
MP0250 DARPin® drug candidate, OsimertinibCOMBINATION_PRODUCT
Sponsors & collaborators
Molecular Partners AGlead sponsor
Mapped research locations
HoustonTexas, United States1DallasTexas, United States1NashvilleTennessee, United States1San DiegoCalifornia, United States1DurhamNorth Carolina, United States1Washington D.C.District of Columbia, United States1OrlandoFlorida, United States1ScottsdaleArizona, United States1DuarteCalifornia, United States1Santa MonicaCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03418532 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.